ANN ARBOR, Mich., Oct. 23, 2017 -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, today announced the Company successfully opened its new research and production headquarters, designed to significantly enhance domestic production of spider silk based fibers and centralize the Company’s research and development program for new polymers, in Michigan.
The Company relocated its production operations from Indiana into its new larger headquarters. Hatching and rearing of silkworms at the new facility has already begun, with three separate strains. Over the next sixty days, the Company plans to expand the new facility’s production.
Kraig Labs is, concurrently, in the process of hiring personnel, in the field of molecular biology, to accelerate the work in engineering exciting new polymers. Individuals with strong laboratory experience working in genetic engineering, and interested in taking a lead role in a fast paced, growing biotechnology company, are encouraged to apply, Click Here.
“It was only earlier this month we announced our plan for the new research and production center,” said Company founder and CEO, Kim K Thompson. “Less than thirty days later the new facility is already up and running, which is a testament to our dedicated employees, who made the transition to our larger new headquarters as seamless and as efficiently as we had hoped. We especially want to thank those who relocated to Michigan to make this next stage in our growth possible. This facility will be dedicated to fulfilling our contract with the Army, moving our product line to commercialization, as well as developing exciting new fibers and materials for unique applications.”
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
[email protected]


Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 



